The LeVe CPAP System was developed to address the increased global demand for respiratory support during the COVID-19 pandemic, specifically aimed at low- and middle-income countries (LMICs).
A study at Mengo Hospital, Uganda, involved 44 patients treated with this CPAP system, revealing a median treatment duration of 7 days and a mortality rate of 49%.
The LeVe CPAP System significantly increased the availability of respiratory support devices at the hospital and was found to be safe and tolerated by patients, playing a crucial role in managing severe COVID-19 cases.